Equity Briefing: Healthcare Review; SXCI, CYTR and MDGN Move

SXC Health Solutions Corp. SXCI rose over 2% thanks to positive note from Credit Suisse. The firm maintained its investment rating on the stock and says the next major catalyst for the company will be its earnings forecasts in its Q2 results. The vote of confidence comes after shareholders approved SXC's merger with Catalyst Health Solutions (CHSI) on Monday.

CytRx CorporationCYTR surged about 7%. Earlier this week, the company announced the U.S. FDA approved its Abbreviated New Drug Application (ANDA) for a generic Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release suspension product. The antitussive/antihistamine combination product is a generic equivalent for the product currently sold under the Tussionex® Pennkinetic® brand name. The product is indicated for the relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children six years of age and older.

Medgenics Inc MDGN climbed over 43% after analysts Sharon di Stefano and Ray Dirks, long-time observers of new chairman, Sol Barer's career put out bullish notes on the firm. di Stefano, who watched the former chairman and CEO of Celgene Corp. CELG build that company into a multi-billion dollar biotech powerhouse and Driks recognized the latest development at Medgenics and believe the cost-effectiveness of MDGN's products all point to significant future shares in multiple sizeable markets.